Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again - Boston Scientific (NYSE:BSX) - Benzinga

Related: Boston Scientific’s Upside With Cardiology Devices Drives Momentum. The company’s cardiovascular segment generated sales of $2.64 billion, rising 17.8% (19.7% operationally and 19% ... Read More

Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations - Boston Scientific (NYSE:BSX) - Benzinga

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ... Read More

How did Boston Scientific get its mojo back?

And with surging demand for two of its devices to treat atrial fibrillation, Boston Scientific’s stock has been on fire — posting a 50-plus percent increase this year alone. Read More

Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors - Seeking Alpha

Turning to the company's balance sheet, I think Boston Scientific appears to be in good shape. At quarter end, the company had a cash pile of $2.9 billion with total debt of $8.9 billion, for a ... Read More

Boston Scientific Remains Operationally Sound But May Have Limited Upside - Seeking Alpha

Boston Scientific recorded Q1 revenues of $3.39bn, a 12% YoY increase, and a net income of $314mn, a 182.88% increase. Read more about BSX stock here. Read More

Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again - Yahoo Finance

Related: Boston Scientific’s Upside With Cardiology Devices Drives Momentum. The company’s cardiovascular segment generated sales of $2.64 billion, rising 17.8% (19.7% operationally and 19% ... Read More